

Masato Okada, MD, FACP, FACR, FAAAAI.

Address Immuno-Rheumatology Center
 St. Luke's International Hospital
 9-1 Akashi-cho Chuo-ku Tokyo 104-8560 Japan

Telephone

e-mail

Occupation

2006.4.-present Chief, Immuno-Rheumatology Center
 St. Luke's International University Hospital, Japan

1997.10.-2006.3 Hôpital Américain de Paris, France

1997.7-1997.9 Research Associate, Full-Time Medical Staff
 Section of Rheumatology
 Yale University, USA

1994.7-1997.6 Academic Clinical Fellow
 Section of Rheumatology
 Section of Allergy& Immunology
 Yale University, USA

1991.7-1994.6 Resident (PGY1-3), Department of Medicine
 Beth Israel Medical Center, New York, USA.

1990.4-1991.6 Resident, Department of Medicine
 Jichi Medical School Hospital, Japan

1989.4-1990.3 Intern
 US Naval Hospital-Yokosuka, Japan.

Education

1989.3. Nara Medical University, Japan Degree M.D.

Award

1996 Markey's Physician-Scientist Award
 Yale University

1997 Senior Rheumatology Scholar Award
 American College of Rheumatology

Affiliation

Visiting Professor

Aichi Medical University

Adjunctive assistant professor

The University of Tokyo (Hospital of Institute of Medical Science)

Graduate School of Medicine, Kyoto University

Oita University School of Medicine

Board Certification

American Board of Internal Medicine

American Board of Rheumatology

American Board of Allergy & Immunology

Japanese Board of Internal Medicine

Japanese Board of Rheumatology

Japanese Board of Allergology

Membership

American College of Rheumatology

GRAPPA

SLEuro etc.

Medical License

Japanese National Medical License

US Medical License (Connecticut State)

Bibliography

- 1) Craft J, Peng S, Fujii T, Okada M, and Fatenejad S. Autoreactive T cells in Murine Lupus: Origins and Roles in Autoantibody Production. *Immunologic Research*. 19(2-3): 245-257, 1999.
- 2) Fujii T, Okada M, Mimori T, Craft J. The Transmembrane form of TNF- α drives autoantibody production in the absence of CD 154: studies using MRL/Mp-Fas lpr mice. *Clin Exp Immunol* 130:224-232, 2002.
- 3) Okada M, Fujii T, Craft J. Regulation of T cell l -dependent autoantibody production by a $\gamma\delta$ T cell line derived from lupus-prone mice. *Cellular Immunology*. 217:23-35, 2002. (dual first author)
- 4) Okada M. Preceptor, pre-accepted? Paving the way for office-based teaching. *Primary Care Japan*. 3:11-16, 2005.
- 5) Fujii T, Okada M, et al. Vaccination with autoreactive CD4+Th1 clones in lupus-prone MRL/Mp-Faslpr/lpr mice *J Autoimmun* 33(2)125-132,2009.
- 6) Mii S, Kobayashi R., Okada M, et al. A histopathologic study of mechanic's hands associated with dermatomyositis: a report of five cases. *Int J Dermatol*. 48:1177-82, 2009.
- 7) Tamaki H, Shimizu H, et Okada M. Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still's disease. *Mod Rheumatol* 20:200-4, 2010.
- 8) Tamaki H, Kishimoto M, Okada M. Iliopsoas bursa rupture mimicking psoas muscle abscess. *Arthritis*

Rheum 62:1769, 2010.

- 9) Nishizaki Y, Tamaki H, et Masato Okada. Comparison between Japanese and Non-Japanese Features of Lupus Cystitis Based on Case Reports Including Novel Therapy and a Literature Review Intern Med 50: 961-968, 2011.
- 10) Nomura A, Fujita Y, Haji Y, Yamaguchi M, Tomino T, Watanabe T, Shimizu H, Okada M.. Baker's cyst in rheumatoid arthritis. Arthritis Rheum 63:774, 2011.
- 11) Rokutanda R, Kishimoto M, Okada M. Magnetic Resonance Angiography in Psoriatic Arthritis of the Hand. J Rheumatol 39(8):1700; doi:10.3899/jrheum.120483, 2012.
- 12) Kishimoto M, Deshpande GA, Yokogawa N, Buyon J, Okada M. Hydroxychloroquine in Japan: a newly rising sun. J Rheumatol 39:1296, 2012.
- 13) Nomura A, Shimizu H, Kishimoto M, Suyama Y, Rokutanda R, Ohara Y, Yamaguchi K, Okada M.. Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis. Lupus. 21(13):1444-9, 2012.
- 14) Kobayashi T, Kishimoto M, Swearingen CJ, Filopoulos MT, Ohara Y, Tokuda Y, Oshikawa H, Yoshida K, Utsunomiya M, Kimura M, Okada M, Matsui K, Yazici Y.. The differences in clinical manifestations, treatment, and concordance rates between two major criteria for Behçet's syndrome in the United States and Japan: data from a large, three-center cohort study. Modern rheumatology 23.3: 547-553, 2013.
- 15) Momose Y, Arai S, Eto h, Kishimoto M, Okada M. Experience with the Use of Hydroxychloroquine for the Treatment of Lupus Erythematosus. J Dermatol. 40(2):94-7, 2013.
- 16) Fukushima Y, Takeda A, Matsutani T, Fukushima F, Furihata T, Maezawa R, Miyoshi M, Hirata H, Sugiyama K, Okada M, Fukuda T. Involvement of Antigen-driven Mechanisms in Interstitial Pneumonia with Polymyositis Rheumatology (Oxford). 52(8):1537-40, 2013.
- 17) K. Yoshida, H. Radner, A. Kavanaugh, Y.-K. Sung, S.-C. Bae, M. Kishimoto, K. Matsui, M. Okada, S. Tohma, M.E. Weinblatt, D.H. Solomon. Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities. Clin Exp Rheumatol 31 (Suppl. 78): S28-S32, 2013.
- 18) Tatsuo Kobayashi, Mitsumasa Kishimoto, Christopher J. Swearingen, Maria T. Filopoulos, Yuri Ohara, Yasuharu Tokuda, Hideto Oshikawa, Kazuki Yoshida, Masako Utsunomiya, Makiko Kimura, Masato Okada, Kazuo Matsui, and Yusuf Yazici. Differences in clinical manifestations, treatment, and concordance rates with two major sets of criteria for Behçet's syndrome for patients in the US and Japan: data from a large, three-center cohort study. Modern rheumatology, 23(3), 547-553, 2013.
- 19) Rokutanda, R., Okada, M., Yamaguchi, K., Nozaki, T., Deshpande, G. A., & Kishimoto, M. Infliximab for Behçet disease with aortic involvement: two novel case reports without concurrent use of immunosuppressive agents or corticosteroids. Modern rheumatology, 23(2), 412-413, 2013.
- 20) Komaru, Y., Higuchi, T., Koyamada, R., Haji, Y., Okada, M., Kamesaki, T., & Okada, S. Primary Sjögren Syndrome Presenting with Hemolytic Anemia and Pure Red Cell Aplasia Following Delivery due to Coombs-negative Autoimmune Hemolytic Anemia and Hemophagocytosis. Internal Medicine, 52(20), 2343-2346, 2013.
- 21) Rokutanda, R., Kishimoto, M., Ohde, S., Shimizu, H., Nomura, A., Suyama, Y., ... & Okada, M. Safety

and efficacy of mizoribine in patients with connective tissue diseases other than rheumatoid arthritis. *Rheumatology international*, 34(1), 59-62, 2014.

- 22) Yamazoe, M., Mizuno, A., Suyama, Y., Nishi, Y., Suzuki, K., Niwa, K., & Okada, M. Endomyocardial biopsy and magnetic resonance imaging of acute myocarditis with adult-onset still's disease. *Korean circulation journal*, 44(6), 437-440, 2014.
- 23) Suyama, Y., Kishimoto, M., Rokutanda, R., Min, C., Deshpande, G. A., Haji, Y., ... & Okada, M. Systemic Capillary Leak Syndrome Successfully Treated with a TNF- α Inhibitor. *J Clin Cell Immunol* 5:5, 2014.
- 24) Nomura, A., Kishimoto, M., Takahashi, O., Deshpande, G. A., Yamaguchi, K., & Okada, M. Prolongation of heart rate-corrected QT interval is a predictor of cardiac autonomic dysfunction in patients with systemic lupus erythematosus. *Rheumatology international*, 34(5), 643-647, 2014.
- 25) Ochi, J., Nozaki, T., Okada, M., Suyama, Y., Kishimoto, M., Akaike, G., ... & Yoshioka, H. MRI findings of the shoulder and hip joint in patients with polymyalgia rheumatica. *Modern Rheumatology*, (0), 1-7, 2015.
- 26) Otsuka, K., Higuchi, T., Nakajima, A., Koyamada, R., Min, C., Okada, M., & Okada, S. Myelodysplastic Syndrome and Polymyalgia Rheumatica Associated With Pernicious Anemia. *Journal of Hematology*, 4(2), 181-183, 2015.
- 27) Ryo Rokutanda, Mitsumasa Kishimoto, Masato Okada. Update on the diagnosis and management of Behçet's disease. *Open Access Rheumatology: Research and Reviews* 7: 1–8, 2015.
- 28) Suyama, Y., Kishimoto, M., Nozaki, T., Deshpande, G. A., & Okada, M. Acute calcific tendinitis of the longus colli muscle. *Arthritis & Rheumatology* 2015 67(9), 2446-2446.
- 29) Ohara, Y., Kishimoto, M., Takizawa, N., Yoshida, K., Okada, M., Eto, H., ... & Tsuji, S. Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan. *The Journal of Rheumatology* 42.8 (2015): 1439-1442..
- 30) Yoshida K, Radner H, Mjaavatten MD, Greenberg JD, Kavanaugh A, Kishimoto M, Matsui K, Okada M, Reed G, Saeki Y, Tohma S, Kremer JM, Solomon DH. Incidence and predictors of biological antirheumatic drug discontinuation attempts among rheumatoid arthritis patients in remission: a Corrona and NinJa collaborative cohort study. *J Rheumatol* 42.12 (2015): 2238-2246.
- 31) Suyama Y, Okada M (dual first authors) et al. "Safety and efficacy of upfront graded administration of trimethoprim–sulfamethoxazole in systemic lupus erythematosus: A retrospective cohort study." *Modern Rheumatology* 26.4 (2016): 557-561.
- 32) Matsuno, H., Okada, M., Sakai, Y., Abe, C., Katayama, K., Sagawa, A., ... & Matsubara, T. (2016). The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis. *Modern rheumatology*, 26(1), 51-56.
- 33) Miyoshi, F., Honne, K., Minota, S., Okada, M., Ogawa, N., & Mimura, T. (2016). A novel method predicting clinical response using only background clinical data in RA patients before treatment with infliximab. *Modern rheumatology*, 26(6), 813-816.
- 34) Yoshida, K., Kishimoto, M., Radner, H., Matsui, K., Okada, M., et al. Low rates of biologic-free clinical

disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry. *Rheumatology* 55.2 (2016): 286-290.

- 35) Suyama, Y., Kishimoto, M., Nozaki, T., Nishimoto, K., & Okada, M. (2016). Man With Swelling in Legs and Forearms. *Annals of emergency medicine*, 68(2), e57-e58.
- 36) Suyama, Y., Kishimoto, M., Togashi, S., Terada, Y., & Okada, M. (2017). Cold-associated painful purple digits due to type I cryoglobulinemia. *Vascular medicine (london, England)*, 22(1), 69.
- 37) Stohl, W., Schwarting, A., Okada, M., Scheinberg, M., Doria, A., Hammer, A. E., ... & Roth, D. (2017). Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled, 52-week study. *Arthritis & Rheumatology* Vol. 69, No. 5, May 2017, pp 1016–1027.
- 38) Kaneshita, S., Kishimoto, M., & Okada, M. (2017). Lupus Enteritis and Cystitis. *Internal Medicine*, 56(4), 467-468.
- 39) Suda, M., Suyama, Y., & Okada, M. (2017). Clinical Images: Widening of Joint Spaces in Acromegaly. *Arthritis & Rheumatology*, 69(5), 1099-1099.
- 40) Rokutanda, R., Tomishima, Y., & Okada, M. (2017). Sarcoid Myofasciitis. *Arthritis & Rheumatology*, 69(9), 1795-1795.
- 41) Mease, P. J., van der Heijde, D., Ritchlin, C. T., Okada, M., Cuchacovich, R. S., Shuler, C. L., ... & Barkham, N. (2016). Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. *Ann Rheum Dis* 2017;76:79–87
- 42) Zenke, Y., Ohara, Y., Kobayashi, D., Arai, S., Kishimoto, M., Okada, M., & Eto, H. (2017). Nail findings in patients with psoriatic arthritis: A cross-sectional study with special reference to transverse grooves. *Journal of the American Academy of Dermatology*, 77(5), 863-867.
- 43) Nash, P., Kirkham, B., Okada, M., Rahman, P., Combe, B., Burmester, G. R., ... & Genovese, M. (2017). Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. *The Lancet*, 389(10086), 2317-2327.
- 44) van der Heijde, D., Gladman, D. D., Kishimoto, M., Okada, M., Rathmann, S. S., Moriarty, S. R., ... & Mease, P. J. (2017). Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). *The Journal of rheumatology*, jrheum-170429.
- 45) ROKUTANDA, R., NISHIHATA, Y., & Okada, M. (2017). IgG4-related Pericoronary Arteritis. *The Journal of rheumatology*, 44(10), 1509-1510.
- 46) Suyama, Y., & Okada, M. (2019). Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?. *Annals of the rheumatic diseases*, 78(2), e17-e17.
- 47) Suda, M., Suyama, Y., Ohde, S., Tsuda, T., Sawada, H., Kishimoto, M., & Okada, M. (2018). Effects of quality indicator monitoring for glucocorticoid-induced osteoporosis and trends of drug treatment in a

Japanese hospital. *International journal of rheumatic diseases*, 21(5), 975-981.

- 48) Suda, M., Ohde, S., Tsuda, T., Kishimoto, M., & Okada, M. (2018). Safety and efficacy of alternate-day corticosteroid treatment as adjunctive therapy for rheumatoid arthritis: a comparative study. *Clinical rheumatology*, 37(8), 2027-2034.
- 49) Kishimoto, M., Yoshida, K., Ichikawa, N., Inoue, H., Kaneko, Y., Kawasaki, T., ... & Takizawa, N. (2019). Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World. *The Journal of rheumatology*, jrheum-180412.
- 50) Uechi, E., Okada, M., & Fushimi, K. (2018). Effect of plasma exchange on in-hospital mortality in patients with pulmonary hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: A propensity-matched analysis using a nationwide administrative database. *PloS one*, 13(4), e0196009.
- 51) Shiraishi, K., Masei, S. U. D. A., Rokutanda, R., Kishimoto, M., & Okada, M. (2018). Mizoribine is as Effective as Methotrexate for the Treatment of Polymyalgia Rheumatica: A Retrospective Case Series Analysis. *Archives of rheumatology*, 33(3), 302.
- 52) Sawada, H., Suda, M., Rokutanda, R., Kobayashi, D., Mitsumasa, K., & Okada, M. (2018). Concomitant use of intravenous methylprednisolone to increase retention rate of abatacept in rheumatoid arthritis. *Rheumatology international*, 38(10), 1825-1831.
- 53) Tanaka, Y., Takeuchi, T., Okada, M., Ishii, T., Nakajima, H., Kawai, S., ... & Tummala, R. (2019). Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. *Modern rheumatology*, 1-8.
- 54) Kamo, M., Nozaki, T., Muraishi, N., Hattori, K., Suzuki, K., Okada, M., & Yamamura, J. (2020). CT Findings of Upper Urinary Tract Lesions in IgG4-Related Disease: Comparison With Urothelial Carcinoma. *American Journal of Roentgenology*, 1-7.
- 55) Suda, M., Kishimoto, M., Ohde, S., & Okada, M. (2020). Validation of the 2019 ACR/EULAR classification criteria of systemic lupus erythematosus in 100 Japanese patients: a real-world setting analysis. *Clinical Rheumatology*, 1-5.
- 56) Nakai, T., Fukui, S., Ikeda, Y., Shimizu, H., Tamaki, H., & Okada, M. (2020). Potential and prognostic factor for belimumab-free remission in patients with systemic lupus erythematosus: a single-center retrospective analysis. *Clinical Rheumatology*, 1-7.
- 57) Fukui, S., Suda, M., Furukawa, S., Tamaki, S., Ikeda, Y., Suyama, Y., ... & Okada, M. (2021). Performance of a pre-administration infection screening questionnaire in patients with rheumatoid arthritis administered biological disease-modifying antirheumatic drugs. *International Journal of Rheumatic Diseases*, 24(5), 647-653.
- 58) Fukui, S., Ikeda, Y., Kataoka, Y., Yanaoka, H., Tamaki, H., Tsuda, T., ... & Okada, M. (2021). Clinical significance of monitoring hypothyroidism in patients with autoimmune rheumatic disease: a retrospective cohort study. *Scientific reports*, 11(1), 1-10.
- 59) Fukui, S., Tamaki, H., & Okada, M. (2021). Emphysematous cystitis in a haemodialysis patient. *Postgraduate Medical Journal*.

- 60) Fukui, S., Kawaai, S., Nakai, T., Suda, M., Ikeda, Y., Nomura, A., ... & Okada, M. (2021). Effectiveness and safety of mizoribine for the treatment of IgG4-related disease: a retrospective cohort study. *Rheumatology*.
- 61) Ota, M., Nagafuchi, Y., Hatano, H., Ishigaki, K., Terao, C., Takeshima, Y., ..., Okada, M., ... & Fujio, K. (2021). Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases. *Cell*, 184(11), 3006-3021.
- 62) Okada, M., Kurimoto, S., Ganz, F., & Boehncke, W. H. (2021). LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan. *PloS one*, 16(1), e0245954.
- 63) Yanaoka, H., Nagafuchi, Y., Hanata, N., Takeshima, Y., Ota, M., Suwa, Y., ..., Okada, M., & Fujio, K. (2021). Identifying the most influential gene expression profile in distinguishing ANCA-associated vasculitis from healthy controls. *Journal of Autoimmunity*, 119, 102617.
- 64) Fukui, S., Suda, M., Furukawa, S., Tamaki, S., Ikeda, Y., Suyama, Y., ... & Okada, M. (2021). Performance of a pre-administration infection screening questionnaire in patients with rheumatoid arthritis administered biological disease-modifying antirheumatic drugs. *International Journal of Rheumatic Diseases*, 24(5), 647-653.
- 65) Fukui, S., Kawaai, S., Nakai, T., Suda, M., Ikeda, Y., Nomura, A., ... & Okada, M. (2021). Effectiveness and safety of mizoribine for the treatment of IgG4-related disease: a retrospective cohort study. *Rheumatology*, 60(12), 5697-5704.
- 66) Matsuno, H., Kang, Y. M., Okada, M., Lee, S. I., Park, S. H., Sheen, D. H., ... & Song, Y. W. (2021). Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate: a 52-week phase III randomised study. *Clinical and Experimental Rheumatology*.
- 67) Fukui, S., Tamaki, H., & Masato, O. (2021). Emphysematous cystitis in a haemodialysis patient. *Postgraduate Medical Journal*.
- 68) Nakai, T., Kitada, A., Fukui, S., & Okada, M. (2021). Risk of adverse pregnancy outcomes in Japanese systemic lupus erythematosus patients with prior severe organ manifestations: A single-center retrospective analysis. *Lupus*, 30(9), 1415-1426.
- 69) Kristensen, L. E., Okada, M., Tillett, W., Leage, S. L., El Baou, C., Sapin, C., ... & de Vlam, K. (2021). Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H. *Rheumatology and therapy*, 1-17.
- 70) Kishimoto, M., Ono, K., Fukui, S., Kawaai, S., Deshpande, G. A., Yoshida, K., ... & Kaname, S. (2021). Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study. *RMD open*, 7(3), e001752.
- 71) Kishimoto, M., Taniguchi, Y., Tsuji, S., Ishihara, Y., Deshpande, G. A., Maeda, K., ... & Kaname, S. (2021). SAPHO Syndrome and Pustulotic Arthro-Osteitis (PAO). *Modern Rheumatology*.

- 72) Ito, T., Fukui, S., Kanie, T., Tamaki, H., & Okada, M. (2022). Immunoglobulin G4-related coronary periarteritis: a systematic literature review with a case series. *Clinical Rheumatology*, 1-15.
- 73) Ono, K., Kishimoto, M., Deshpande, G. A., Fukui, S., Kawaai, S., Sawada, H., .Okada,M,... & Kaname, S. (2022). Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis. *Rheumatology International*, 1-16.
- 74) Kawato, R., Rokutanda, R., Okada, M., Matsushita, M., Yamaji, K., & Tamura, N. (2022). Effect of Prophylactic Dose of Trimethoprim-Sulfamethoxazole on Serum Creatinine in Japanese Patients With Connective Tissue Diseases. *Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders*, 15, 11795441221085141.
- 75) Fukui, S., Tamaki, H., & Okada, M. (2022). Transient Empty Portal Vein With Gastric Emphysema. *Clinical Gastroenterology and Hepatology*, 20(4), A15-A16.
- 76) Kristensen, L. E., Okada, M., Tillett, W., Leage, S. L., El Baou, C., Sapin, C., ... & de Vlam, K. (2022). Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H. *Rheumatology and therapy*, 9(1), 109-125.
- 77) Fukui, S., Nakai, T., Kawaai, S., Ikeda, Y., Suda, M., Nomura, A., ... & Okada, M. (2022). Advantages of an alternate-day glucocorticoid treatment strategy for the treatment of IgG4-related disease: A preliminary retrospective cohort study. *Medicine*, 101(39), e30932.
- 78) Nakai, T., Fukui, S., Ikeda, Y., Suda, M., Tamaki, H., & Okada, M. (2022). Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis. *Lupus Science & Medicine*, 9(1), e000682.
- 79) Nakai, T., Fukui, S., Kidoguchi, G., Ikeda, Y., Kitada, A., Nomura, A., ... & Okada, M. (2022). Effect and safety profile of belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus. *Clinical Rheumatology*, 1-11.
- 80) Nakai, T., Ikeda, Y., Yamaguchi, K., Asano, T., Iwata, F., Kidoguchi, G., ... & Okada, M. (2023). A case report of two systemic lupus erythematosus pregnancies with early placental exposure to belimumab: Case report with review. *Modern Rheumatology Case Reports*, 7(1), 82-86.
- 81) Tanaka, Y., Atsumi, T., Okada, M., Miyamura, T., Ishii, T., Nishiyama, S., ... & Takeuchi, T. (2023). The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis. *Modern Rheumatology*, 33(1), 134-144.
- 82) Fukui, S., Okada, M., Rahman, M., Matsui, H., Shiraishi, A., Nakai, T., ... & Yoshida, K. (2023). Differences in the Association Between Alcoholic Beverage Type and Serum Urate Levels Using Standardized Ethanol Content. *JAMA Network Open*, 6(3), e233398-e233398.
- 83) Nakai, T., Fukui, S., Sawada, H., Ikada, Y., Tamaki, H., Kishimoto, M., & Okada, M. (2023). Disease-modifying effect and long-term safety of belimumab in patients with systemic lupus erythematosus: A single-center retrospective study. *Lupus*, 32(13), 1518-1527.
- 84) Nakai, T., Honda, N., Soga, E., Fukui, S., Kitada, A., Yokogawa, N., & Okada, M. (2024). A retrospective analysis of the safety of tacrolimus use and its optimal cut-off concentration during pregnancy in women

with systemic lupus erythematosus: study from two Japanese tertiary referral centers. *Arthritis Research & Therapy*, 26(1), 1-13.

- 85) Atsumi, T., Bae, S. C., Gu, H., Huang, W. N., Li, M., Nikpour, M., .Okada,M.. & Mekanji, Y. (2023). Risk Factors for Pulmonary Arterial Hypertension in Patients With Systemic Lupus Erythematosus: A Systematic Review and Expert Consensus. *ACR Open Rheumatology*, 5(12), 663-676.
- 86) Watanabe, M., Haji, Y., Hozumi, M., Amari, Y., Mizuno, Y., Ito, T., ... & Okada, M. (2023). Combined B-cell immunomodulation with rituximab and belimumab in severe, refractory TAFRO syndrome associated with Sjögren's syndrome: A case report. *Modern Rheumatology Case Reports*, 7(2), 475-479.
- 87) Fukui, S., Okada, M., Shinozaki, T., Asano, T., Nakai, T., Tamaki, H., ... & Solomon, D. H. (2024). Changes in alcohol intake and serum urate changes: longitudinal analyses of annual medical examination database. *Annals of the Rheumatic Diseases*.
- 88) Fukui, S., Okada, M., Shinozaki, T., Suzuki, T., Nakai, T., Ozawa, H., ... & Solomon, D. H. Weight Reduction and Target Serum Urate Level: A Longitudinal Study of Annual Medical Examination. *Arthritis & Rheumatology*.
- 89) Tanaka, Y., Atsumi, T., Okada, M., Miyamura, T., Ishii, T., Nishiyama, S., ... & Takeuchi, T. (2024). The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis. *Modern Rheumatology*, 34(4), 720-731.
- 90) Nakai, T., Honda, N., Soga, E., Fukui, S., Kitada, A., Yokogawa, N., & Okada, M. (2024). Effect of remission, clinical remission with active serology, and glucocorticoid dosage on the pregnancy outcome of pregnant patients with systemic lupus erythematosus. *Arthritis research & therapy*, 26(1), 63.
- 91) Nakai, T., Honda, N., Soga, E., Fukui, S., Kitada, A., Yokogawa, N., & Okada, M. (2024). A retrospective analysis of the safety of tacrolimus use and its optimal cut-off concentration during pregnancy in women with systemic lupus erythematosus: study from two Japanese tertiary referral centers. *Arthritis Research & Therapy*, 26(1), 15.
- 92) Fukui, S., Okada, M., Shinozaki, T., Asano, T., Nakai, T., Tamaki, H., ... & Solomon, D. H. (2024). Changes in alcohol intake and serum urate changes: longitudinal analyses of annual medical examination database. *Annals of the rheumatic diseases*, 83(8), 1072-1081.
- 93) Suda, M., Dai, K., Yamaguchi, T., Muranaka, K., Minoda, M., & Okada, M. (2025). Anifrolumab as a glucocorticoid-sparing agent in MRI-negative myelitis associated with neuropsychiatric lupus: A case report. *Modern Rheumatology Case Reports*, 9(2), rxaf065.
- 94) Billa, S., Fukui, S., Paudel, M. L., Suzuki, T., Imai, R., Kim, Y., ... Okada, M. & Solomon, D. H. (2025). Longitudinal Changes in Serum Urate Levels from Pre-menopause through Post-menopause: Interrupted Time-Series Analyses. *Arthritis & Rheumatology*.
- 95) Nakai, T., Fukui, S., Ikeda, Y., Suda, M., Tamaki, H., Kishimoto, M., & Okada, M. (2025). The Impact of Early Belimumab Use on Successful Glucocorticoid Tapering to a Low Maintenance Dose in Treatment-naïve, Newly Diagnosed Systemic Lupus Erythematosus. *International Journal of Rheumatic Diseases*, 28(11), e70462.

- 96) Sawada, H., Kishimoto, M., Tada, K., Deshpande, G. A., Kobayashi, D., Okada, M., ... & Tamura, N. (2025). Disease phenotype and management of axial psoriatic arthritis in Japan compared with other regions, particularly other Asian countries: results of the ASAS-PerSpA study. *BMC rheumatology*, 9(1), 130.
- 97) Tanaka, Y., Atsumi, T., Okada, M., Miyamura, T., Ishii, T., Nishiyama, S., ... & Takeuchi, T. (2025). Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 study. *Modern rheumatology*, 35(3), 470-477.
- 98) Tanaka, Y., Atsumi, T., Okada, M., Miyamura, T., Ishii, T., Nishiyama, S., ... & Takeuchi, T. (2025). Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 study. *Modern rheumatology*, 35(3), 470-477.
- 99) Tanaka, Y., Atsumi, T., Okada, M., Miyamura, T., Ishii, T., Nishiyama, S., ... & Takeuchi, T. (2025). Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial. *Modern Rheumatology*, 35(3), 458-469.
- 100) Shiba, H., Ozawa, H., & Okada, M. (2025). Polymyalgia Rheumatica Presenting as Fever of Unknown Origin. *JMA journal*, 8(2), 622-623.
- 101) Perez-Alamino, R., Maldonado-Ficco, H., Moltó, A., Waimann, C., Maldonado-Cocco, J., Dougados, M., ... & Van den Bosch, F. (2025). Trends to shorter diagnostic delay in spondyloarthritis patients during the last decades and association with clinical presentation: data from ASAS-COMOSPA study. *RMD open*, 11(1), e004756.

24 January, 2026

To The Executive Committee SLEuro (European Lupus Society)

From Masato Okada, MD, Director, Immuno–Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan

RE: Motivation for Nomination to the SLEuro Executive Committee

Dear Members of the Executive Committee,

It is with great honor and enthusiasm that I submit my nomination for a position on the Executive Committee of SLEuro. Having dedicated my entire medical career to the research and treatment of Systemic Lupus Erythematosus (SLE), I have long regarded SLEuro as the most authoritative and pivotal organization in our field.

While I am currently based in Japan, serving as the Director of the Rheumatology Center at a major teaching hospital, my career has been defined by a truly international trajectory that connects Japan, the United States, and Europe. I believe this unique background allows me to offer a distinct and valuable perspective to the committee.

My global journey began with my clinical training in New York, followed by advanced fellowship training at Yale University. Subsequently, I had the privilege of practicing medicine in Paris, France, for nine years from 1997 to 2006. This decade spent in the European medical community gave me a deep appreciation for the diversity of healthcare systems and patient care approaches across Europe.

Although I have since returned to Japan to lead a major rheumatology center, I have maintained a global outlook. I understand that applying from outside Europe is unconventional; however, I see this as a strength. I am uniquely positioned to act as a bridge between the European lupus community and the wider global context, including Asia.

I am eager to contribute my clinical expertise, my experience in navigating diverse medical cultures, and my unwavering commitment to advancing SLE research to the society. I would be honored to serve SLEuro and support its mission to improve the lives of lupus patients worldwide.

Thank you for your time and consideration.

Sincerely,

Masato Okada, MD